Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Medtronic
Colorcon
Daiichi Sankyo
Argus Health

Generated: April 21, 2019

DrugPatentWatch Database Preview

BETASERON Drug Profile

« Back to Dashboard

US Patents for BETASERON

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Pathologica LLC (San Francisco, CA) ➤ Try a Free Trial RX Orphan search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial ➤ Try a Free Trial RX Orphan search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Cetus Corporation (Emeryville, CA) ➤ Try a Free Trial RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Cetus Corporation (Emeryville, CA) ➤ Try a Free Trial RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Cetus Corporation (Emeryville, CA) ➤ Try a Free Trial RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Cetus Corporation (Emeryville, CA) ➤ Try a Free Trial RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23 ➤ Try a Free Trial Cetus Corporation (Emeryville, CA) ➤ Try a Free Trial RX Orphan company
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for BETASERON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
16C1017 France ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
2016/052 Ireland ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
96C0019 Belgium ➤ Try a Free Trial PRODUCT NAME: BETAFERON INTERFERON BETA-1B; REGISTRATION NO/DATE: EU/1/95/003/001 19951130
CA 2016 00058 Denmark ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
C20160039 00209 Estonia ➤ Try a Free Trial PRODUCT NAME: DAKLIZUMAB;REG NO/DATE: EU/1/16/1107 05.07.2016
93315 Luxembourg ➤ Try a Free Trial PRODUCT NAME: PROCEDE DE TRAITEMENT DE LA SCLEROSE MULTIPLE - DACLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1107
CR 2016 00058 Denmark ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Covington
Deloitte
Healthtrust
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.